Physician

Gloria Ortiz, M.D.

According to 2025 Medicare claims, Gloria Ortiz, M.D. (NPI: 1871825307) practices endocrinology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is GLORIA ORTIZ, MD, P.A. (NPI: 1669980058; TIN: 820955288) and primary practice location at 78503-1589. Ortiz is affiliated with the RGV ACO Health Providers, LLC (ACO ID: D0257), participating under the REACH model.

Ortiz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 514 traditional Medicare patients, billed 13,327 HCPCS/CPT codes, and received $424,613 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,472 prescription claims across 452 beneficiaries totaling $550,790 in drug costs, led by Mounjaro (Tirzepatide). DME data shows 133 claims. Open Payments data shows 214 records totaling $467,556. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $46,535 to $424,613. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $149,242 and ending at $550,790. In contrast, DME billing represents a smaller volume and rose steadily, from $1,252 to $45,788.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	206	1,062	$46,535
2017	344	3,598	$172,889
2018	131	1,046	$62,158
2019	314	2,869	$142,310
2020	395	6,034	$245,365
2021	461	7,392	$277,633
2022	353	4,537	$162,463
2023	450	8,081	$261,161
2024	514	13,327	$424,613

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	130	470	$149,242
2016	410	3,449	$1,520,388
2017	541	5,358	$2,559,940
2018	527	3,072	$1,559,200
2019	438	2,717	$1,587,478
2020	400	1,988	$976,279
2021	415	2,151	$1,086,056
2022	436	1,634	$803,959
2023	491	1,913	$1,144,595
2024	452	1,472	$550,790

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	105	164	$4,961
2017	176	322	$8,147
2018	64	163	$1,661
2019	43	176	$16,806
2020	N/R	76	$8,277
2021	N/R	73	$11,916
2022	40	195	$36,565
2023	32	243	$47,676
2024	32	133	$42,177

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	427	956	$91
82306	Vitamin d-3 level	257	354	$28
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	315	559	$13
84439	Thyroxine (thyroid chemical), free	245	410	$9
36415	Insertion of needle into vein for collection of blood sample	373	703	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Mounjaro	Tirzepatide	77	3,283	$116,815
Ozempic	Semaglutide	65	2,554	$82,754
Jardiance	Empagliflozin	49	3,480	$60,124
Synjardy Xr	Empagliflozin/Metformin Hcl	29	1,845	$33,642
Kerendia	Finerenone	31	1,125	$23,208

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	32	119	$41,864
A4253	Blood glucose test or reagent strips for home blood glucose monitor, per 50 strips	N	N/R	14	$313

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	94	$69,088	Novo Nordisk Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	120	$398,468	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gloria Ortiz, M.D.?

Tedicare shows public-source Medicare data for Gloria Ortiz, M.D. (NPI 1871825307), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gloria Ortiz, M.D. have ACO affiliation data?

Gloria Ortiz, M.D. is shown with ACO affiliation data for RGV ACO Health Providers, LLC (REACH, ACO ID D0257).

What billing organization is linked to Gloria Ortiz, M.D.?

Gloria Ortiz, M.D. is linked to GLORIA ORTIZ, MD, P.A. (billing NPI 1669980058) in the available physician profile data.

Does Gloria Ortiz, M.D. have Open Payments data?

Gloria Ortiz, M.D. has 214 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.